_glow-study-mrd-outcomes-after-fixed-duration-ibrven-versus-clbo-for-first-line-treatment-of-cll-in-elderly-or-unfit-pati.jpg "Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients from umrd Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 3 min 48 sec
✓ Published: 14-Dec-2021
✓ Published: 14-Dec-2021
Description:
Dr Arnon Kater speaks to ecancer about the Glow study. nnThis is the first prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients. nnInitially, he explains the background of the Glow study. nnDr Kater then discusses the methods and key results. All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that
Dr Arnon Kater speaks to ecancer about the Glow study. nnThis is the first prospective data on minimal residual disease (MRD) outcomes after fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of CLL in elderly or unfit patients. nnInitially, he explains the background of the Glow study. nnDr Kater then discusses the methods and key results. All-oral, once-daily, fixed-duration Ibr+Ven demonstrated superior uMRD responses that
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 34 seconds 👁 49
_icll07-filo-study-minimal-residual-disease-still-detectable-after-first-line-combination-therapy.webp "Prof Feugier speaks with ecancer at EHA 23 about results from a phase II trial of treating CLL with induction obinutuzumab and ibrutinib.nnHe describes how CR with undetectable residual disease (uMRD) may be associated with a longer survival in CLL.nnWith a manageable toxicity profile, 48% CR rate and 12.5% uMRD at 9 months, Prof Feugier describes the need for further research and further rounds of immunochemotherapy to fully induce uMRD.")
⏲ 2 min 20 sec ✓ 17-Jun-2018
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.webp "CLL Society")
⏲ 10 minutes 21 seconds 👁 125
_ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-treatment-dr-bill-wierda-ash-2022.webp "CLL Society")
⏲ 6 minutes 39 seconds 👁 117
_captivate-fixed-duration-first-line-treatment-with-ibrutinib-plus-venetoclax-for-cll-sll.webp "Dr Rajat Bannerji speaks to ecancer about the CAPTIVATE study. nnIt is a trial investigating a fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL. nnInitially, he explains the background of the study. Dr Bannerji then discusses the methodology and results of the study. nnHe mentions that first-line I+V is an all-oral, once-daily, chemotherapy-free, fixed-duration regimen that provides deep, durable responses in patients with CLL/SLL, including those with genomic high-")
⏲ 6 min 82 sec ✓ 10-Jun-2021
_manduul-and-delgerel-hashimoto39s-disease.webp "MANDUULERO")
⏲ 1 hour 1 minute 19 seconds 👁 39.9K
_captivate-study-outcomes-in-patients-with-umrd-following-cessation-of-ibrutinib-plus-venetoclax.jpg)
_icll07-filo-study-minimal-residual-disease-still-detectable-after-first-line-combination-therapy.jpg)
_captivate-ibrutinib-venetoclax-delivers-high-rates-of-umrd-in-cll.jpg)
_liso-cel-induces-rapid-umrd-transcend-cll-004-update.jpg)
_mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-therapy-for-cll-ash-2023.jpg)
_ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-treatment-dr-bill-wierda-ash-2022.jpg)
_captivate-fixed-duration-first-line-treatment-with-ibrutinib-plus-venetoclax-for-cll-sll.jpg)
_manduul-and-delgerel-hashimoto39s-disease.jpg)
![[+]](/images/menu.gif){kind=small}